PREDICTION OF Aedes aegypti DEVELOPMENT INHIBITION THROUGH DOCKING BETWEEN AaMps1 KINASE AND INHIBITOR SP600125 AND PROTEOMIC ANALYSIS OF Aedes aegypti TREATMENT WITH SP600125

The Aedes aegypti mosquito is a vector of several diseases and since it is an arthropod it has all the proteins common to eukaryotes, among them Mps1, a dual-specificity kinase already well characterized in metazoa and that has been functionally related to mitotic checkpoint (SAC). SP600125 it is reversible inhibitors that act by blocking the phosphorylation of Mps1. Studies on the action of the inhibitor SP600125 on the development and post-treatment proteomic analysis of A. aegypti are non-existent.